The generic name for Rexulti is brexpiprazole [1].
What is brexpiprazole used for?
Brexpiprazole is a medication used to treat major depressive disorder (MDD) and schizophrenia [1]. For MDD, it is used as an adjunctive treatment, meaning it is taken in addition to an antidepressant [1]. In schizophrenia, it is indicated for the treatment of psychosis in adults [1].
How does brexpiprazole work?
Brexpiprazole is classified as an atypical antipsychotic [1]. It works by affecting the activity of neurotransmitters in the brain, specifically dopamine and serotonin. By modulating these chemical messengers, brexpiprazole helps to regulate mood and thought processes [1].
When will the Rexulti patent expire?
The patent protection for Rexulti has a complex expiry timeline with various patents covering different aspects of the drug. According to DrugPatentWatch.com, the primary patents related to brexpiprazole formulations and methods of use have expiration dates that extend into the late 2020s and early 2030s [2]. However, patent litigation and potential challenges can impact these dates.
Can generic versions of Rexulti be approved before patent expiry?
Generic drug manufacturers may attempt to challenge existing patents or develop their own versions of brexpiprazole that do not infringe on current patents. The U.S. Food and Drug Administration (FDA) approves generic drugs only after the relevant patents have expired or have been successfully challenged [3].
What are the risks associated with brexpiprazole?
Like many antipsychotic medications, brexpiprazole carries a risk of serious side effects. These can include an increased risk of death in elderly patients with dementia-related psychosis, although this risk is not specific to brexpiprazole and is a general warning for this class of drugs [1]. Other potential serious side effects include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (such as hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain), and orthostatic hypotension [1]. Patients should discuss all potential risks with their healthcare provider.
How does brexpiprazole compare to other depression and schizophrenia medications?
Brexpiprazole is one of several atypical antipsychotics used for schizophrenia and as an adjunctive treatment for depression [1]. Other medications in this class, such as aripiprazole (Abilify) and quetiapine (Seroquel), are also used for similar indications and work through related neurotransmitter pathways. The choice of medication often depends on individual patient responses, side effect profiles, and specific treatment goals [1].
Where can I find more information on brexpiprazole patents?
Detailed information on patents related to brexpiprazole, including expiration dates and any ongoing litigation, can be found on specialized databases such as DrugPatentWatch.com [2].
Who manufactures Rexulti?
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd. [1].
Sources:
1. https://www.rexulti.com/
2. https://drugpatentwatch.com/
3. https://www.fda.gov/drugs/generic-drugs